Extract
The coronavirus disease 2019 (COVID-19) pandemic has inflicted a considerable pressure on populations, healthcare systems and community organisations worldwide, due to the fast spread of the disease and its huge global burden of morbidity and mortality, healthcare resource consumption, and societal and economic implications [1].
Abstract
Production of guidance in rapidly evolving areas where evidence is absent or fragile is challenging and needs to use rigorous methods interpreted with caution https://bit.ly/3jpChqk
Footnotes
Provenance: Commissioned article, peer reviewed
Conflict of interest: N. Roche has nothing to disclose.
Conflict of interest: T. Tonia is a European Respiratory Society Methodologist.
Conflict of interest: A. Bush has nothing to disclose.
Conflict of interest: C. Brightling has nothing to disclose.
Conflict of interest: M. Kolb reports grants from the Canadian Pulmonary Fibrosis Foundation, Canadian Institute for Health Research, Alkermes and Actelion; other funding from Roche, Boehringer Ingelheim and European Respiratory Journal; grants and other funding from Pulmonary Fibrosis Foundation; grants and personal fees from Boehringer Ingelheim, Roche Canada and Prometic; and personal fees from Gilead, outside the submitted work.
Conflict of interest: A-T. Dinh-Xuan has nothing to disclose.
Conflict of interest: M. Humbert reports grants, personal fees and non-financial support from GlaxoSmithKline; personal fees from AstraZeneca, Novartis, Roche, Sanofi, Teva and Merck; and grants and personal fees from Acceleron, Actelion and Bayer, outside the submitted work.
Conflict of interest: A. Simonds has nothing to disclose.
Conflict of interest: Y. Adir has nothing to disclose.
- Received September 23, 2020.
- Accepted September 25, 2020.
- Copyright ©ERS 2020.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.